The Enlightened Esquire

When you or a loved one is facing a terminal diagnosis, every decision carries weight. The pursuit of comfort, dignity, and meaningful options often becomes as important as medical treatment itself. In recent years, innovative approaches to end-of-life care have begun reshaping what is possible — particularly through Right-to-Try legislation and psychedelic-assisted therapy. Yet accessing these pathways isn’t simple. The legal landscape is complex, rapidly evolving, and filled with both opportunity and obstacles.

The Right-to-Try framework

The federal Right-to-Try Act of 2018 created a pathway for patients with life-limiting diagnoses to pursue investigational treatments that have cleared initial (Phase 1) safety testing but are not yet approved. It minimizes FDA involvement and places responsibility with the patient, treating physician, and drug sponsor. Importantly, Right-to-Try removes an FDA hurdle — it does not, on its own, override the Controlled Substances Act for Schedule I substances, a limit the Ninth Circuit underscored in AIMS v. DEA (2025).

Psychedelic-assisted therapy: breaking new ground

Among the most promising frontiers in end-of-life care is psychedelic therapy. Clinical research has shown that psilocybin and MDMA can reduce depression, anxiety, and the existential distress that often accompanies terminal illness. The FDA has granted Breakthrough Therapy designation to several of these treatments, and in 2025–2026 psilocybin cleared two Phase 3 trials — but access today remains limited and heavily regulated. The honest task is mapping the narrow, lawful avenues that genuinely exist.

Why specialized guidance matters

• Constantly changing law — federal updates, state legislation, and local initiatives all move quickly.
• Time-sensitive applications — many pathways carry strict deadlines.
• A medical-legal bridge — advocacy that speaks to clinicians, regulators, and families alike.

Explore your options

If you or a loved one is facing a terminal diagnosis and want to understand the lawful pathways, reach out: 📧 deja@correia.law  ·  📞 (619) 251-1432.

This article is educational and is not legal advice; it creates no attorney–client relationship. Psychedelics remain predominantly Schedule I under federal law. Always seek independent, licensed counsel before acting.